Which medication is commonly used for medical closure of a patent ductus arteriosus (PDA)?

Indomethacin is commonly used for the medical closure of a patent ductus arteriosus (PDA) in neonates, particularly premature infants. This non-steroidal anti-inflammatory drug (NSAID) inhibits the production of prostaglandins, which are responsible for keeping the ductus arteriosus open. By reducing prostaglandin levels, indomethacin facilitates the closure of the PDA, helping to prevent potential complications associated with a persistently patent ductus.

Indomethacin is particularly effective due to its targeted action on the ductal tissue, and it is often administered when the PDA is causing significant hemodynamic concerns, helping to normalize circulation and improve oxygen delivery to the body. Its use in clinical practice has shown beneficial outcomes, particularly in preterm infants, where the closure of a PDA can significantly impact respiratory and cardiac function.